Constitutive activation of Stat 3 oncogene product in human ovarian carcinoma cells

Gynecologic Oncology

Volumn 79, Issue 1, 2000, Pages 67-73

  Huang, Melinda ^a   Page, Carmen ^a   Reynolds, R Kevin ^a   Lin, Jiayuh ^a  

^a UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

Author keywords

Bcl X(L); Cyclin D1; Ovarian cancer; Stat 3

Indexed keywords

CYCLIN D1; GENE PRODUCT; PROTEIN BCL X; STAT3 PROTEIN;

ARTICLE; CARCINOGENESIS; CARCINOMA CELL; CONTROLLED STUDY; DNA FLANKING REGION; FEMALE; GENE ACTIVATION; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; MALIGNANT TRANSFORMATION; ONCOGENE; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REPORTER GENE; SIGNAL TRANSDUCTION;

EID: 0033781642     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.2000.5931     Document Type: Article

References (53)

1. Neoplastic diseases of the ovary
2. Epithelial ovarian cancer
3. Transcriptional responses to polypeptide ligands: The JAK-STAT pathway
4. STAT 3 and G-CSF-induced myeloid differentiation
5. Granulocyte colony-stimulating factor activates a 72-kDa isoform of STAT 3 in human neutrophils
6. STAT 3 and STAT 4: Members of the family of signal transducers and activators of transcription
7. STAT 3: A STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6
8. STATs and gene regulation
9. Elevated levels of members of the STAT family of transcription factors in breast carcinoma nuclear extracts
10. Differential activation of STATs 3 and 5 during mammary gland: Development
11. Role of epidermal growth factor receptor and STAT 3 activation in autonomous proliferation of SUM-102PT human breast cancer cells
12. Constitutive activation of STAT 3 in fibroblasts transformed by diverse oncoproteins and in breast carcinoma cells
13. Inhibition of pp60-Src reduces Bcl-x(L) expression and reverses the transformed phenotype of cells overexpressing EGF and HER-2 receptors
14. STAT 3 activation is required for cellular transformation by v-src
15. Constitutive activation of STAT 3 signaling confers resistance to apoptosis in human U266 myeloma cells
16. Bcl-x(L) is expressed in ovarian carcinoma and modulated chemotherapy-induced apoptosis
17. 1 expression is associated with features of malignancy and disease recurrence in ovarian tumors
18. 1 in epithelial ovarian cancers
19. 1 and CDK4 genes in ovarian carcinomas
20. Sporadic CDKN2 (MTS1/p16ink4) gene alterations in human ovarian tumours
21. Growth suppression of human ovarian cancer cell lines by the introduction of a p16 gene via a recombinant adenovirus
22. STAT proteins as novel targets for cancer therapy
23. STAT 3 activation by Src induces specific gene regulation and is required for cell transformation
24. A new human ovarian carcinoma cell line: Establishment and analysis of tumor-associated markers
25. Cisplatin and paclitaxel induced apoptosis of ovarian carcinoma cells and the relationship between Bax and Bak upregulation and the functional status of p53
26. Radiation survival parameters of antineoplastic drug-sensitive and -resistant human ovarian cancer cell lines and their modification by buthionine sulfoximine
27. Induction of apoptosis in cisplatin-sensitive and resistant human ovarian cancer cell lines
28. One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice
29. Rare activation of the TCF/beta-catenin pathway in ovarian cancer
30. A simplified method to culture human ovarian surface epithelium
31. Human ovarian surface epithelium in primary culture
32. Serial propagation of human ovarian surface epithelium in tissue culture
33. Organotypic culture of human ovarian surface epithelial cells: A potential model for ovarian carcinogenesis
34. The effects of platelet-derived growth factor and receptor on normal and neoplastic human ovarian surface epithelium
35. Primary ovarian cancer cultures are resistant to Fas-mediated apoptosis
36. STAT 3 as an oncogene
37. Reflections on STAT3, STAT5, and STAT6 as fat STATs
38. Overexpression of Akt/AKT can modulate chemotherapy-induced apoptosis
39. AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas
40. Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas
41. Disruption of epithelial cell-matrix interactions induces apoptosis
42. 2-terminal kinase and induction of apoptosis after detachment of epithelial cells
43. Jak-Stat signaling induced by the v-abl oncogene
44. Stat 3 plays an important role in oncogenic Ros- and insulin-like growth factor I receptor-induced anchorage-independent growth
45. Direct interaction of Jak 1 and v-Abl is required for v-Abl-induced activation of Stats and proliferation
46. A single amino acid substitution in the v-Eyk intracellular domain results in activation of Stat 3 and enhances cellular transformation
47. Inhibition of constitutively activated STAT 3 correlates with altered Bcl-2/Bax expression and induction of apoptosis in mycosis fungoides tumor cells
48. Bcl-X, a BCl-2-related gene that functions as a dominant regulator of apoptotic cell death
49. Acute-phase response factor, a nuclear factor binding to acute-phase response elements, is rapidly activated by interleukin-6 at the posttranslational level
50. Gene therapy with dominant-negative STAT 3 suppresses growth of the murine melanoma B16 tumor in vivo
51. 1 to S cell-cycle transition
52. Functional differences between STAT 3α and STAT 3β
53. STAT 3β, a splice variant of transcription factor STAT 3, is a dominant negative regulator of transcription